1228837-05-5

Basic information

• Product Name: 4'-chloro-5,5-diMethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde
• Synonyms: 4'-chloro-5,5-diMethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde;2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexene-1-carboxaldehyde;2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexene-1-carbaldehyde;2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-enecarboxaldehyde;2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarbaldehyde;1-Cyclohexene-1-carboxaldehyde, 2-(4-chlorophenyl)-4,4-dimethyl-
• CAS NO: 1228837-05-5
• Molecular Formula: C₁₅H₁₇ClO
• Molecular Weight: 248.74788
• Mol File: 1228837-05-5.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 347.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.147±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 4'-chloro-5,5-diMethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-chloro-5,5-diMethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde(1228837-05-5)
• EPA Substance Registry System: 4'-chloro-5,5-diMethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde(1228837-05-5)

Safety Data

• Hazardous Substances Data: 1228837-05-5(Hazardous Substances Data)

Usage

Uses

2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexene-1-carboxaldehyde is an intermediate in various reactions. For example, its an intermediate in preparation of N-?(phenylsulfonyl)?benzamides and N-?(3-?pyridylsulfonyl)?benzamides as apoptosis-?inducing agents for the treatment of cancer and immune diseases and autoimmune diseases.

Upstream product

• 2979-19-3 3,3-dimethylcyclohexanone 
• 17151-48-3 tributyl(4-chlorophenyl)stannane 
• 251980-67-3 2-bromo-4,4-dimethylcyclohex-1-ene-1-carbaldehyde 
• 1679-18-1 4-Chlorophenylboronic acid 
• 1228780-51-5 (4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 1228943-80-3 2-chloro-4,4-dimethyl-2-oxocyclohexenecarbaldehyde 

Downstream Products

• 1228780-71-9 tert-butyl 4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazine-1-carboxylate 
• 1228874-96-1 methyl 2-(1-(bis(4-methoxyphenyl)methyl)-1H-benzo[d]imidazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)benzoate 
• 1628047-87-9 1-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl) piperazine dihydrochloride 
• 1235865-77-6 [2-((1H-pyrrolo [2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid] 
• 1257044-40-8 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide 
• 1228780-51-5 (4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 

Relevant articles and documents

Mild and Robust Stille Reactions in Water using Parts Per Million Levels of a Triphenylphosphine-Based Palladacycle

An inexpensive and new triphenylphosphine-based palladacycle has been developed as a pre-catalyst, leading to highly effective Stille cross-coupling reactions in water under mild reaction conditions. Only 500–1000 ppm of Pd suffices for couplings involving a variety of aryl/heteroaryl halides with aryl/hetaryl stannanes. Several drug intermediates can be prepared using this catalyst in aqueous nanoreactors formed by 2 wt % Brij-30 in water.

1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES

The present invention relates to lH-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for treating neoplastic, autoimmune or neurodegenerative diseases. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 162 to 233; examples 1 to 8; table; compound examples cpd-1 to cpd-135; biological examples 1 to 4).

BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS

The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.